Wedbush Cuts Earnings Estimates for Apogee Therapeutics

Apogee Therapeutics, Inc. (NASDAQ:APGE) – Research analysts at Wedbush reduced their Q1 2025 earnings estimates for Apogee Therapeutics in a research note issued to investors on Monday, March 3rd. Wedbush analyst D. Nierengarten now forecasts that the company will earn ($1.24) per share for the quarter, down from their previous forecast of ($0.99). Wedbush currently has a “Outperform” rating and a $90.00 target price on the stock. The consensus estimate for Apogee Therapeutics’ current full-year earnings is ($3.09) per share. Wedbush also issued estimates for Apogee Therapeutics’ Q2 2025 earnings at ($1.26) EPS, Q3 2025 earnings at ($1.21) EPS, Q4 2025 earnings at ($1.21) EPS, FY2025 earnings at ($4.92) EPS, FY2026 earnings at ($5.07) EPS, FY2027 earnings at ($5.56) EPS and FY2028 earnings at ($7.00) EPS.

Apogee Therapeutics (NASDAQ:APGE) last announced its earnings results on Monday, March 3rd. The company reported ($1.19) EPS for the quarter, missing the consensus estimate of ($0.94) by ($0.25).

Several other research analysts have also recently commented on the stock. Canaccord Genuity Group started coverage on shares of Apogee Therapeutics in a report on Monday, November 25th. They set a “buy” rating and a $89.00 target price for the company. Canaccord Genuity Group started coverage on shares of Apogee Therapeutics in a report on Monday, November 25th. They set a “buy” rating and a $89.00 target price for the company. Finally, Guggenheim restated a “buy” rating on shares of Apogee Therapeutics in a report on Monday, February 10th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $91.60.

Apogee Therapeutics Trading Up 2.0 %

Shares of APGE opened at $36.14 on Thursday. Apogee Therapeutics has a 12 month low of $29.10 and a 12 month high of $72.29. The firm has a fifty day simple moving average of $39.12 and a 200 day simple moving average of $47.02. The stock has a market capitalization of $1.63 billion, a price-to-earnings ratio of -14.93 and a beta of 2.46.

Hedge Funds Weigh In On Apogee Therapeutics

Several large investors have recently modified their holdings of the stock. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Apogee Therapeutics in the fourth quarter valued at about $6,521,000. GF Fund Management CO. LTD. bought a new position in shares of Apogee Therapeutics in the fourth quarter valued at about $43,000. Neo Ivy Capital Management bought a new position in shares of Apogee Therapeutics in the fourth quarter valued at about $1,745,000. Woodline Partners LP raised its position in shares of Apogee Therapeutics by 4.0% in the fourth quarter. Woodline Partners LP now owns 1,015,608 shares of the company’s stock valued at $46,007,000 after purchasing an additional 39,453 shares during the period. Finally, Soleus Capital Management L.P. bought a new position in shares of Apogee Therapeutics in the fourth quarter valued at about $3,171,000. 79.04% of the stock is owned by institutional investors.

Insider Buying and Selling at Apogee Therapeutics

In related news, Director Mark C. Mckenna acquired 20,000 shares of the company’s stock in a transaction dated Thursday, December 12th. The shares were bought at an average cost of $49.54 per share, with a total value of $990,800.00. Following the completion of the transaction, the director now directly owns 20,000 shares of the company’s stock, valued at $990,800. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Carl Dambkowski sold 4,540 shares of the stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $48.76, for a total transaction of $221,370.40. Following the completion of the transaction, the insider now directly owns 258,073 shares in the company, valued at $12,583,639.48. The trade was a 1.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 53,735 shares of company stock worth $2,247,762 over the last quarter. 36.10% of the stock is currently owned by insiders.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.